
PepGen Inc (PEPG) Stock Forecast & Price Target
PepGen Inc (PEPG) Analyst Ratings
Bulls say
PepGen Inc. has presented encouraging initial data from the FREEDOM-DM1 trial, demonstrating a dose-dependent increase in splicing correction, with nearly a four-fold efficacy increase observed from 5 mg/kg to 10 mg/kg doses, thus validating its Enhanced Delivery Oligonucleotide (EDO) platform. The company’s efforts to advance its lead product, PGN-EDODM1, indicate significant potential for therapeutic benefits, as evidenced by a splicing correction of 29.1%, surpassing the established benchmark for clinical relevance. Moreover, the absence of safety issues during trials provides a robust foundation for continued optimism about PepGen’s pipeline products and overall strategy in the neuromuscular disease therapeutic landscape.
Bears say
PepGen reported a significant net loss of $22 million or $0.68 per share for the fourth quarter of 2024, raising concerns about its financial sustainability amid ongoing clinical challenges. The company's probability of success for its lead product, PGN-EDO51, has been reduced from 40% to 25% due to safety concerns related to kidney function issues and the risk of clinical failures, which may impact regulatory approval in key markets such as the US and EU. Additionally, there are uncertainties regarding PGN-EDO51's ability to achieve peak commercial revenue, compounded by potential market size limitations and penetration rates, further contributing to a negative outlook for the stock.
This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.
PepGen Inc (PEPG) Analyst Forecast & Price Prediction
Start investing in PepGen Inc (PEPG)
Order type
Buy in
Order amount
Est. shares
0 shares